The autoimmune diagnostic company expects its new assay to be available by the end of this year or in early 2027.

Improvement in results on a noninvasive urinary biomarker panel at 3 months among patients with lupus nephritis predicted a clinical response at 1 year. A noninvasive urinary biomarker panel predicts ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are confirmed in larger studies, research presented here suggested. Measurement of 12 ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing ...

WASHINGTON — An investigational 12-protein panel of urinary biomarkers predicted histologically active lupus nephritis (LN) with 86% accuracy, according to research presented at the American College ...

The FDA approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. Obinutuzumab is just the third ...

Roche Holding said the Food and Drug Administration approved a drug for the treatment of adults with lupus nephritis, a potentially life-threatening autoimmune disease that commonly affects the ...